Shingrix Heart Benefit Tracks the Adjuvant, Not Shingles

Adults 60 and older given Shingrix had a 9% lower heart-disease burden over seven years than peers who got Zostavax, the older live shingles vaccine. Oxford researchers published the comparison Wednesday in Nature Medicine, using America’s 2017 switch between the two shots as a natural experiment. The paper’s own figures undercut extra shingles prevention as the driver.

Both groups chose to get vaccinated. That design was meant to cut the “healthy vaccinee” problem that haunts studies of people who skip shots. What remains is a smaller, fading signal that tracks the chemical booster inside Shingrix, and a large randomized trial in Denmark that is already enrolled.

A Calendar Cutoff Split Two Vaccinated Cohorts

Shingles is a painful flare of the chickenpox virus that hides in nerves after childhood. The U.S. moved in October 2017 from Merck’s live weakened shot, Zostavax, to GSK’s protein-based Shingrix. First author Fabiana Corsi-Zuelli, a research fellow in psychiatry at the University of Oxford, and senior author Maxime Taquet, an associate professor of psychiatry there, treated that swap as a natural experiment.

They pulled electronic records from TriNetX, a network of 60 health systems that does not include people with public health insurance. They matched adults 60 and older vaccinated in April through September 2017 with adults vaccinated in the same months of 2018, using propensity scores so the groups looked alike on recorded health traits. Each arm had 36,460 people.

HOW THE TWO SHOTS WERE SPLIT

1. April to September 2017: 98.6% of the earlier cohort receive Zostavax, the live vaccine then still in routine use.
2. October 2017: Shingrix displaces the live shot in U.S. practice after its approval.
3. April to September 2018: 93.5% of the later matched cohort receive Shingrix.
4. Seven years of follow-up: the team tracks ischemic heart disease, heart failure, and ischemic stroke as a combined endpoint.

People vaccinated a year apart should not differ in diet, wealth, or caution in ways that line up neatly with a regulatory cutoff. The authors also checked tetanus-diphtheria-pertussis shots given in those same months of 2017 and 2018 and found no matching swing in recorded heart events, which argues against a simple change in how hospitals coded disease.

The comparison is not vaccinated versus unvaccinated. Both groups got a shingles shot. The live vaccine is the control because earlier work found it had no heart effect of its own. An unmeasured confounder would still only need a 1.42-fold imbalance, the paper’s E-value, to wash the result out, which is a modest bar.

Heart Failure Fell 12% Across Seven Years

The recombinant vaccine was associated with a 9 percent decrease in cardiovascular burden over seven years, reported as a restricted mean time lost ratio of 0.91 (95% confidence interval 0.88 to 0.95). In plainer terms, the Shingrix group spent 9% more time free of the combined heart diagnosis.

Heart failure and coronary disease drove the result in both sexes. Stroke fell in men, whose event rate was 15% higher, and was not statistically clear in women. There was no linked drop in myocarditis, peripheral arterial disease, hemorrhagic stroke, or transient ischemic attack. A similar-sized move in ST-elevation heart attacks did not reach statistical significance.

On an absolute scale the paper calls a 0.8% difference in cumulative ischemic heart disease and heart failure “clinically meaningful” if trials confirm it, because it would translate into hundreds of thousands of cases avoided in the United States. STAT, which first detailed the briefing, put the overall absolute gap at about 1% fewer cardiovascular events after seven years. New Scientist, citing the same briefing, said that by 3.5 years 10.9% of the Zostavax group had at least one of heart failure, stroke, or clogged heart arteries, against 9.6% after Shingrix.

Kaleen Hayes, associate director of pharmacoepidemiology at Brown University School of Public Health, who was not on the paper, told STAT she was excited to see the result. “This was really the next question everyone was wondering about,” she said, after years of mixed signals on whether the shot helps the heart as well as the brain.

Why the Shingles-Prevention Story Falls Short

Shingrix prevents far more shingles than Zostavax, and shingles itself raises heart risk, so the obvious story is that fewer rashes mean fewer clots. The Oxford group tested that idea against its own data and said it looks unlikely, because the extra shingles cases prevented are too few, too late, and the wrong shape to carry a 1.5-point heart gap.

THREE GAPS THE RASH CANNOT FILL

• Case counts: The absolute difference in shingles between the two vaccines was less than 0.5% at mid-follow-up, against a 1.5% drop in ischemic heart disease.
• Timing: A benefit that came only from blocked shingles should build slowly as cases accrue in the live-vaccine group; the heart curves split early.
• The live-shot control: A prior natural experiment of Zostavax versus no vaccine found no reduced risk of heart disease or stroke, so extra viral control from a better shot is a weak explanation on its own.

Betty Raman, an associate professor of cardiovascular medicine at Oxford and a co-author, told STAT’s briefing that ischemic heart disease is tied to an inflammatory response, in which cytokines can push fat into artery walls and help form blockages. If Shingrix is doing something to those signals, stopping a rash is not the whole job.

Mark Russell, a clinical senior lecturer and consultant rheumatologist at King’s College London, said in a Science Media Centre note that the individual benefit is relatively small, but millions of people receive shingles vaccination, so even a small heart benefit could mean a large number of events avoided at population scale. That arithmetic only holds if the association is real.

AS01 Retrains Monocytes, Then the Benefit Fades

Shingrix pairs varicella-zoster glycoprotein E with AS01, an adjuvant that Zostavax does not contain. Taquet told the briefing the heart hypothesis is stronger for the adjuvant than for viral blockade, because live-vaccine studies have not shown heart protection. Corsi-Zuelli said the recombinant vaccine may induce trained immunity, meaning lasting changes in immune cells that can alter cytokines and the cells lining blood vessels.

The Nature Medicine paper points at work showing AS01 can reprogram monocytes, including reduced interleukin-6 responses after Toll-like receptor activation, and notes that IL-6 blocking is causally tied to lower heart risk. A separate University of Colorado team reported in PLOS Pathogens in December 2025 that Shingrix generated trained immunity in monocytes for five years, through persistent downregulation of TGFβ1, while the live vaccine’s innate effect on dendritic cells faded by 90 days. That lab finding is not proof of a heart mechanism, but it is the kind of durable innate shift the Oxford authors are now invoking.

Hayes still treats the split as open. “Whether it’s the actual AS01 versus just in general, it’s an effective vaccine and our immune system gets keyed up is, I think, very much still on the table as to what’s the potentially right answer here,” she told STAT.

The association itself thinned with time. Protection against ischemic heart disease and heart failure was present in the first 3.5 years, then hazard ratios lost significance and the gap in cumulative cases flattened. The authors wrote that such a time-limited immune change would support studies of repeated vaccination at regular intervals. A one-time shingles series is not, on this evidence, a permanent heart shield.

GSK also puts AS01 in Arexvy, its RSV vaccine for older adults, and in the RTS,S malaria shot. This paper does not test those products. If AS01 is doing vascular work, those shots become the next place to look, and that is a question for trials, not for this records study.

Dementia Came First, by 164 Diagnosis-Free Days

The same Oxford group used the same U.S. switch in a 2024 Nature Medicine paper on dementia. Adults who mainly received Shingrix had a 17% increase in diagnosis-free time over six years compared with those who mainly received Zostavax, a restricted mean time lost ratio of 0.83 (95% confidence interval 0.80 to 0.87). Among people who later got a dementia diagnosis, that translated into 164 extra diagnosis-free days. Each arm had 103,837 people aged 65 and older. The dementia signal was present in both sexes and larger in women, and Shingrix also beat flu and tetanus-diphtheria-pertussis shots in conventional matched comparisons.

Hayes’s own work has tracked dementia after Shingrix in older adults. The heart paper is the sequel that group of researchers had been waiting for, using a tighter window around the 2017 cutoff and a younger age floor of 60. It is still the same design family: two vaccinated cohorts, electronic diagnoses, no randomization.

Taquet has been careful in public not to sell either finding as a reason to skip the rash. He said people should get the vaccine for shingles protection in the first instance, and that extra brain and heart signals, if they hold up, would be a bonus that might nudge uptake.

Two-Dose Coverage Still Stops Short of One in Three

CDC already recommends two doses of Shingrix from age 50 for adults with healthy immune systems, spaced 2 to 6 months apart, and two doses from age 19 for people who are or will be immunodeficient. The agency says the shot was 97% effective against shingles in adults 50 to 69 with healthy immune systems and 91% effective in adults 70 and older. There is no maximum age, and a prior bout of shingles or a prior Zostavax dose is not a reason to skip it.

Uptake has not caught that advice. CDC’s 2024 National Health Interview Survey found that 28.7 percent of adults 50 and older had completed both recombinant doses, up from 1.1% in 2018. Among adults 60 and older, the group in the Oxford heart paper, two-dose coverage was 33.4%. Among adults 65 and older it was 35.0%. At ages 50 to 59 it was 19.4%.

Racial gaps are wide. Among adults with an indication, any-dose coverage was 44.8% in White adults, 31.6% in Black adults, 30.5% in Hispanic adults, and 50.3% in Asian adults. The Oxford records also exclude public insurance, so they miss much of the Medicare population that carries the highest heart risk. If a small per-person heart benefit is real, the people least present in this dataset are the ones with the most events to prevent.

A Truveta analysis published in June 2026 found that 14.0% of adults who turned 50 in 2024 got at least one Shingrix dose within a year of becoming eligible, against 2.6% of those who turned 50 in 2018. Completion among those who started was better: 74.5% finished the second dose within a year. Starting, not finishing, is the leak.

Denmark Has Already Randomized 162,000 Adults

Taquet said the heart study remains observational even as a natural experiment, and that the team wants randomized trials. One is underway. DAN-ZOSTER, listed as NCT07485283, is a nationwide Danish phase 4 trial that randomly assigns Shingrix or no study vaccine. ClinicalTrials.gov lists a planned enrollment of 162,000 adults aged 65 or older, with dual primary endpoints of major adverse cardiovascular events (non-fatal heart attack, non-fatal stroke, or cardiovascular death) and incident dementia. The trial actually started on April 28, 2026. The registry’s estimated primary completion is April 2029. Taquet told reporters first results are anticipated in 2027. Danish coverage of the launch said heart outcomes can be counted sooner than dementia, with dementia results expected around 2029. Enrolment is now closed, the study’s public site says.

If confirmed, Shingrix could prevent hundreds of thousands of cardiovascular events in the USA alone, and may be the first vaccine that protects the heart and the brain.

Maxime Taquet, associate professor of psychiatry, University of Oxford, media briefing

In a separate press statement he said vaccinating older adults against shingles could prevent hundreds of thousands of coronary heart diseases, strokes, and cases of heart failure worldwide if trials confirm the signal, calling it one of the more impactful interventions on offer for brain and heart in later life. Raman has asked for more trials to define who should be treated if the benefit extends beyond today’s age bands. That does not change CDC’s present reason for the shot, which is shingles and postherpetic neuralgia.

The live question left by Wednesday’s paper is narrower than the headlines. It is whether AS01, or the strong innate response it kicks off, can be treated as a vascular drug that happens to come in a shingles syringe, and whether a booster would be needed as the seven-year curves flatten. Denmark is already asking that in random assignment. Until those counts arrive, the 0.8-point absolute gap is a lead, not a prescription.

Disclaimer: This article is news reporting and analysis of a published observational study and related trials; it is for information only. It is not medical advice, a vaccination recommendation, or a substitute for a clinician’s judgment about your heart risk, immune status, or vaccine schedule. Speak with a licensed physician or other qualified clinician before starting, delaying, or changing any vaccine or heart treatment. Figures, coverage rates, and trial timelines reflect the sources as of August 27, 2026, and may change as CDC updates estimates and as DAN-ZOSTER reports results.